WAVE.V -- Pharma company offering oncology/COVID-19 drugs
Big jump in this little known Canadian pharma's stock price this morning on news of market authorization of their drugs in multiple European countries. Tiny float makes for big moves up and down. Good speculative buy on pullback in the .20s, IMO.
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries
WINNIPEG, MB, July 30, 2020 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited, has been granted marketing authorization for Pemetrexed and Bortezomib in multiple countries across Europe.
About Pemetrexed
Pemetrexed is an injectable chemotherapy product used in the treatment of pleural mesothelioma and non-small cell lung cancer along with other indications. The Company has obtained marketing authorization for this product in numerous countries including Belgium, the Czech Republic, Germany, Ireland, the Netherlands, and the United Kingdom and is in the process of filing for market authorization in additional countries across Europe.
About Bortezomib
Bortezomib is an injectable chemotherapy product used to treat multiple myeloma and mantle cell lymphoma along with other indications. The Company has obtained marketing authorization for this product in numerous countries including Belgium, Denmark, France, Germany, Ireland, the Netherlands, Norway, Spain, Sweden and the United Kingdom and is in the process of filing for market authorization in additional countries across Europe.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective, and affordable cancer therapeutics in the EU, United Kingdom and North American market. The Company, through its subsidiary, is currently selling three generic oncology products in the United Kingdom, namely capecitabine, temozolomide and erlotinib. In addition, the Company is developing two generic oncology products in Europe, namely pemetrexed and bortezomib and additional products in the United States. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries
WINNIPEG, MB, July 30, 2020 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited, has been granted marketing authorization for Pemetrexed and Bortezomib in multiple countries across Europe.
About Pemetrexed
Pemetrexed is an injectable chemotherapy product used in the treatment of pleural mesothelioma and non-small cell lung cancer along with other indications. The Company has obtained marketing authorization for this product in numerous countries including Belgium, the Czech Republic, Germany, Ireland, the Netherlands, and the United Kingdom and is in the process of filing for market authorization in additional countries across Europe.
About Bortezomib
Bortezomib is an injectable chemotherapy product used to treat multiple myeloma and mantle cell lymphoma along with other indications. The Company has obtained marketing authorization for this product in numerous countries including Belgium, Denmark, France, Germany, Ireland, the Netherlands, Norway, Spain, Sweden and the United Kingdom and is in the process of filing for market authorization in additional countries across Europe.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective, and affordable cancer therapeutics in the EU, United Kingdom and North American market. The Company, through its subsidiary, is currently selling three generic oncology products in the United Kingdom, namely capecitabine, temozolomide and erlotinib. In addition, the Company is developing two generic oncology products in Europe, namely pemetrexed and bortezomib and additional products in the United States. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.
Comment:
75% of the 54M float is held by insiders!! Around 13M shares are free trading.
Comment:
~ $1M in cash per last financials. $200K+ quarterly revenue pre COVID-19. Never had to do a capital raise since IPO. Should see substantial bump in revenues this year.
Comment:
Also collaborating with the University of Manitoba on COVID-19 treatment.
Waverley Pharma Announces Collaboration with Dr. David E. Herbert and the University of Manitoba for the Development of a Synthetic Library of Chloroquine Analogs to Treat COVID-19
WINNIPEG, MB, June 25, 2020 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), an emerging Canadian pharmaceutical company, is pleased to announce it has entered into an Industrial Research Collaboration Agreement (the "Agreement") with the University of Manitoba to undertake a research and development project entitled "Production of a Synthetic Library of Chloroquine Analogs and Precursors for Immediate and Future Development of COVID-19 Treatments." The funding for this project is provided by the Natural Sciences and Engineering Research Council of Canada (NSERC) under its Alliance COVID-19 Grants program.
Dr. David E. Herbert will serve as the Principal Investigator of the project. Dr. Herbert is currently an Associate Professor in the Department of Chemistry in addition to serving as the Faculty of Science Research Chair in Fundamental Science (Physical Sciences) at the University of Manitoba.
Waverley Pharma is granted exclusive worldwide intellectual property and commercial rights to any resulting products or technology developed under the Agreement in exchange for paying a royalty to the University of Manitoba on future sales of such products or technology.
About University of Manitoba, Faculty of Science
At the Faculty of Science at the University of Manitoba, we take seriously our mission to produce the research scientists who invent a better future for us all, and to educate all those who pass through the University of Manitoba doors – the doctors, nurses, scientists, engineers, lawyers, accountants, entrepreneurs, CEOs, social scientists, artists, and educators. At the Faculty of Science we believe science is for everyone.
About NSERC
NSERC aims to make Canada a country of discoverers and innovators for the benefit of all Canadians. The agency supports students in their advanced studies, promotes and supports discovery research, and fosters innovation by encouraging Canadian organizations to participate and invest in postsecondary research projects. NSERC researchers are on the vanguard of science, building on Canada's long tradition of scientific excellence.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective and affordable cancer therapeutics in the EU and North American market. The Company, through its subsidiary, is selling two generic oncology products in the United Kingdom, namely capecitabine and temozolomide and has three additional generic products under development. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.
Waverley Pharma Announces Collaboration with Dr. David E. Herbert and the University of Manitoba for the Development of a Synthetic Library of Chloroquine Analogs to Treat COVID-19
WINNIPEG, MB, June 25, 2020 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), an emerging Canadian pharmaceutical company, is pleased to announce it has entered into an Industrial Research Collaboration Agreement (the "Agreement") with the University of Manitoba to undertake a research and development project entitled "Production of a Synthetic Library of Chloroquine Analogs and Precursors for Immediate and Future Development of COVID-19 Treatments." The funding for this project is provided by the Natural Sciences and Engineering Research Council of Canada (NSERC) under its Alliance COVID-19 Grants program.
Dr. David E. Herbert will serve as the Principal Investigator of the project. Dr. Herbert is currently an Associate Professor in the Department of Chemistry in addition to serving as the Faculty of Science Research Chair in Fundamental Science (Physical Sciences) at the University of Manitoba.
Waverley Pharma is granted exclusive worldwide intellectual property and commercial rights to any resulting products or technology developed under the Agreement in exchange for paying a royalty to the University of Manitoba on future sales of such products or technology.
About University of Manitoba, Faculty of Science
At the Faculty of Science at the University of Manitoba, we take seriously our mission to produce the research scientists who invent a better future for us all, and to educate all those who pass through the University of Manitoba doors – the doctors, nurses, scientists, engineers, lawyers, accountants, entrepreneurs, CEOs, social scientists, artists, and educators. At the Faculty of Science we believe science is for everyone.
About NSERC
NSERC aims to make Canada a country of discoverers and innovators for the benefit of all Canadians. The agency supports students in their advanced studies, promotes and supports discovery research, and fosters innovation by encouraging Canadian organizations to participate and invest in postsecondary research projects. NSERC researchers are on the vanguard of science, building on Canada's long tradition of scientific excellence.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective and affordable cancer therapeutics in the EU and North American market. The Company, through its subsidiary, is selling two generic oncology products in the United Kingdom, namely capecitabine and temozolomide and has three additional generic products under development. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.
Trade closed: target reached